Sign in

    Kevin Strang

    Research Analyst at Goldman Sachs Group

    Kevin Strang is an Equity Analyst specializing in Biopharma and Biotechnology research at Goldman Sachs Group, where he analyzes and covers leading companies in these sectors. He previously served as Vice President at Jefferies LLC, building a strong foundation in equity research before joining Goldman Sachs. Known for his expertise in evaluating pharmaceutical and biotechnology firms, Strang has contributed to investment insights that support high-value decision-making; however, specific performance metrics and rankings are not publicly disclosed. Dr. Strang holds advanced professional credentials and is recognized for his analytical rigor in the healthcare and biotech industries.

    Kevin Strang's questions to Syndax Pharmaceuticals (SNDX) leadership

    Kevin Strang's questions to Syndax Pharmaceuticals (SNDX) leadership • Q2 2025

    Question

    Kevin Strang, on behalf of Corinne Johnson, inquired about the Revuforge treatment timeline, asking how many cycles typically occur before a stem cell transplant and what proportion of patients are ultimately expected to receive post-transplant maintenance therapy.

    Answer

    CEO Michael Metzger explained that patients typically receive Revuforge for two to three cycles before proceeding to transplant. He noted that while about one-third of commercial patients have gone to transplant so far, this rate is expected to increase as the drug is used in earlier lines of therapy. He added that physicians intend to put the vast majority, potentially 70-90%, of eligible patients back on maintenance therapy post-transplant.

    Ask Fintool Equity Research AI